Ocrelizumab for treating relapsing–remitting multiple sclerosis

Marketing authorisation indication

Ocrelizumab (Ocrevus, Roche) has a marketing authorisation in the UK 'for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features'.

Dosage in the marketing authorisation

Ocrelizumab is administered by intravenous infusion. The first dose is administered as 2×300 mg infusions 2 weeks apart; subsequent doses are administered as a single 600 mg infusion every 6 months. A minimum interval of 5 months should be maintained between each dose.

Price

The list price for ocrelizumab is £4,790 per 300‑mg vial (company submission).

The company has a commercial arrangement. This makes ocrelizumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.